Plaque Psoriasis

The phase 3 DISCREET study explored the safety and efficacy of apremilast in treating patients with moderate to severe genital psoriasis over 32 weeks.

From diagnosis, investigators sought to explore psoriasis characteristics, patient demographics, patterns of treatment, and disease progression.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

This analysis suggests a potential causal association between psoriasis and depression, highlighting the need for mental health screening in patients with psoriasis.

This systematic review and meta-analysis looked at research on the efficacy and safety of topical roflumilast 0.3% in patients with plaque psoriasis.

This review of November 2025 highlights several notable news stories covered in the dermatology space.

In this analysis, investigators explored potential impacts of antibiotic exposure on the persistence of biologic treatments in patients living with psoriasis.

This global analysis highlights the incidence of psoriasis around the world by 2025, noting various distinctions in region, age groups, and sex.

The Psoriasis Study of Health Outcomes (PSoHO) was designed as a 36-month, non-interventional, international cohort study of patients with psoriasis.

The FDA acceptance of Arcutis's supplemental New Drug Application (sNDA) was announced for roflumilast cream 0.3% (Zoryve).

In a session presented at the SDPA Fall Conference, Karan Lal, DO, spoke on the topic of GLP-1 agonist drugs for weight loss and their connection to dermatology.

At the 2025 SDPA Fall Conference, Laura Bush, DMSc, PA-C, presented the next iteration of an IMID and Obesity bootcamp session.

In this review of the month of October, HCPLive highlights some of the most significant dermatology news updates.

These phase 4 data from the UnlIMMited trial highlight the efficacy and safety of risankizumab for psoriasis in the genital or scalp region.

Panelists discuss how the ICONIC-LEAD placebo-controlled studies showed icotrokinra achieving clear or almost clear skin in about 75% of patients at week 24, representing unprecedented efficacy for an oral psoriasis therapy.

In this interview, Swanson highlights the topics covered in her session on oral and injectable medications, and specifically icotrokinra, in the psoriasis pipeline.

Song interviewed with the team regarding his session, discussing recent data on IL-23 inhibition in patients with psoriasis.

At Week 52, icotrokinra achieved clear/almost clear skin in 72% of patients with scalp psoriasis and 85% with genital psoriasis, with consistent safety and durable responses.

Panelists discuss how the head-to-head ICONIC-ADVANCE studies demonstrated icotrokinra’s superior efficacy vs deucravacitinib, with approximately double the complete clearance rates and a safety profile similar to placebo.

Panelists discuss how icotrokinra represents a novel oral peptide that selectively blocks the IL-23 receptor, offering the trusted safety profile of IL-23 inhibition in an oral formulation with high selectivity and no off-target effects.

This systematic review and meta-analysis highlights tildrakizumab’s efficacy in Asian patients versus the efficacy of other biologic options.

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.